Read More

Biden’s Urgent Action Against Antibiotic-Resistant Bacteria – Allocates $100M to Battle Deadly Superbugs

U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.  More than a million people worldwide succumb to infections caused by antibiotic-resistant bacteria annually, as reported by the World Health Organization. 

AMD

Read More

On September 21, Bluebird Bio And Lonza Entered Into A Second Amendment To The Master Manufacturing Services Agreement, Dated June 3, 2016, As Amended October 23, 2017 – 8k

https://www.sec.gov/ix?doc=/Archives/edgar/data/1293971/000129397123000046/blue-20230921.htm Under the Lonza Agreement, Lonza manufactures drug product used for the Company’s gene therapies, ZYNTEGLO and SKYSONA.

BLUE